Annual Current Liabilities
$19.60 M
+$5.13 M+35.43%
December 31, 2023
Summary
- As of February 7, 2025, LYRA annual total current liabilities is $19.60 million, with the most recent change of +$5.13 million (+35.43%) on December 31, 2023.
- During the last 3 years, LYRA annual current liabilities has risen by +$14.71 million (+301.25%).
- LYRA annual current liabilities is now at all-time high.
Performance
LYRA Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$14.95 M
-$4.32 M-22.42%
September 30, 2024
Summary
- As of February 7, 2025, LYRA quarterly total current liabilities is $14.95 million, with the most recent change of -$4.32 million (-22.42%) on September 30, 2024.
- Over the past year, LYRA quarterly current liabilities has dropped by -$4.28 million (-22.26%).
- LYRA quarterly current liabilities is now -23.69% below its all-time high of $19.60 million, reached on December 31, 2023.
Performance
LYRA Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
LYRA Current Liabilities Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +35.4% | -22.3% |
3 y3 years | +301.3% | -22.3% |
5 y5 years | +899.9% | -22.3% |
LYRA Current Liabilities Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +35.4% | -23.7% | +51.5% |
5 y | 5-year | at high | +301.3% | -23.7% | +279.4% |
alltime | all time | at high | +899.9% | -23.7% | +279.4% |
Lyra Therapeutics Current Liabilities History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $14.95 M(-22.4%) |
Jun 2024 | - | $19.28 M(+2.9%) |
Mar 2024 | - | $18.72 M(-4.5%) |
Dec 2023 | $19.60 M(+35.4%) | $19.60 M(+1.9%) |
Sep 2023 | - | $19.23 M(+36.3%) |
Jun 2023 | - | $14.11 M(-0.3%) |
Mar 2023 | - | $14.15 M(-2.2%) |
Dec 2022 | $14.47 M | $14.47 M(+6.4%) |
Sep 2022 | - | $13.61 M(+37.8%) |
Jun 2022 | - | $9.87 M(-44.5%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2022 | - | $17.80 M(-2.4%) |
Dec 2021 | $18.25 M(+273.6%) | $18.25 M(+2.7%) |
Sep 2021 | - | $17.77 M(+201.0%) |
Jun 2021 | - | $5.90 M(+41.6%) |
Mar 2021 | - | $4.17 M(-14.6%) |
Dec 2020 | $4.88 M(-6.2%) | $4.88 M(+3.7%) |
Sep 2020 | - | $4.71 M(+19.4%) |
Jun 2020 | - | $3.94 M(-23.6%) |
Mar 2020 | - | $5.16 M(-1.0%) |
Dec 2019 | $5.21 M(+165.7%) | $5.21 M |
Dec 2018 | $1.96 M | - |
FAQ
- What is Lyra Therapeutics annual total current liabilities?
- What is the all time high annual current liabilities for Lyra Therapeutics?
- What is Lyra Therapeutics annual current liabilities year-on-year change?
- What is Lyra Therapeutics quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Lyra Therapeutics?
- What is Lyra Therapeutics quarterly current liabilities year-on-year change?
What is Lyra Therapeutics annual total current liabilities?
The current annual current liabilities of LYRA is $19.60 M
What is the all time high annual current liabilities for Lyra Therapeutics?
Lyra Therapeutics all-time high annual total current liabilities is $19.60 M
What is Lyra Therapeutics annual current liabilities year-on-year change?
Over the past year, LYRA annual total current liabilities has changed by +$5.13 M (+35.43%)
What is Lyra Therapeutics quarterly total current liabilities?
The current quarterly current liabilities of LYRA is $14.95 M
What is the all time high quarterly current liabilities for Lyra Therapeutics?
Lyra Therapeutics all-time high quarterly total current liabilities is $19.60 M
What is Lyra Therapeutics quarterly current liabilities year-on-year change?
Over the past year, LYRA quarterly total current liabilities has changed by -$4.28 M (-22.26%)